Market Overview on Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline landscape.

Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder. The frequency and intensity of psoriasis is affected by environmental factors such as smoking, sun exposure, alcoholism, and HIV infection. The symptoms of psoriasis include red patchy skin covered with silver scales, small scaling spots; dry cracked skin that may bleed; burning, itching, soreness, thickened, pitted or ridged nails; joint swelling and stiffening, and dandruff-like scaling over the scalp. Psoriasis is primarily diagnosed through an examination of the skin by dermatologist, as there are no blood tests or laboratory tests for a diagnosis of psoriasis.

Complete report available @ Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 20, 26, 13, 2, 11, 8 and 1 respectively for Plaque Psoriasis (Psoriasis Vulgaris).

Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AbbVie Inc AbGenomics International, Inc. Almirall, S.A. Alteogen Inc. Amgen Inc. AstraZeneca Plc Avexxin AS BIOCAD Biocon Limited Bionovis SA Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CalciMedica, Inc. Can-Fite BioPharma Ltd. Cell Medica Limited Cellceutix Corporation Coherus BioSciences, Inc. Eli Lilly and Company Epirus Biopharmaceuticals, Inc. Exicure, Inc. Forward Pharma A/S Genor BioPharma Co Ltd GlaxoSmithKline Plc Idera Pharmaceuticals, Inc. Johnson & Johnson Kadmon Corporation, LLC Kang Stem Biotech Co., Ltd. KPI Therapeutics, Inc. LEO Pharma A/S Lipidor AB Lupin Limited Lycera Corp. Maruho Co., Ltd. MetrioPharm AG Mitsubishi Tanabe Pharma Corporation Momenta Pharmaceuticals, Inc. Mycenax Biotech Inc. NeuClone Pty Ltd Novartis AG Oncobiologics, Inc. Pfizer Inc. Promius Pharma, LLC Protalix BioTherapeutics, Inc. Provectus Biopharmaceuticals, Inc. Sandoz International GmbH Shanghai Celgen Bio-Pharmaceutical Co., Ltd. Sucampo Pharmaceuticals, Inc. Sun Pharma Advanced Research Company Ltd. Takeda Pharmaceutical Company Limited TheraMAB LLC Therapeutic Proteins International, LLC UCB S.A. Valeant Pharmaceuticals International, Inc. XBiotech Inc Ziarco Pharma Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###